Bristol Myers Squibb & Co. (NYSE:BMY) reported fourth-quarter 2025 revenues of $12.50 billion on Thursday, beating the consensus of $12.281 billion, a 1% increase year over year.
“We made significant progress in 2025, with real momentum in our Growth Portfolio and a strengthened balance sheet that provides the strategic flexibility to continue investing in growth drivers,” said Christopher Boerner, board chair and CEO, Bristol Myers Squibb.
“2026 is data-rich, and we are advancing a truly differentiated pipeline with multiple pivotal readouts expected in the back half of the year. Our core business is strong and growing, and we have the potential to achieve industry-leading, sustainable growth into the 2030s and beyond,” Boerner commented.
Bristol-Myers reported adjusted earnings of $1.26, beating the consensus of $1.11, down 25%, which includes the impacts of acquired IPRD charges and …